Body dysmorphic disorder in patients attending a dermatology clinic in Nigeria: sociodemographic and clinical correlates^*

Abstract:

Background:

Body dysmorphic disorder is a relatively common psychiatric disorder in the context of dermatology and cosmetic and plastic surgery but is underdiagnosed and underreported in Africa.

Objective:

To evaluate the prevalence of body dysmorphic disorder and symptoms of anxiety/depression and determine their sociodemographic and clinical correlates.

Methods:

A systematic random sampling design was made to recruit 114 patients with skin diseases. Sociodemographic and clinical data were obtained. The Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive-Compulsive Scale, Hospital Anxiety and Depression Scale was administered, and data were analyzed using SPSS 20.

Results:

Mean age of participants was 37.70±17.47 years, and 67/114 (58.8%) were females. Prevalence of body dysmorphic disorder was 41/114 (36.0%), and prevalence of anxiety/depression symptoms was 35/114 (30.7%). Prevalence of body dysmorphic disorder in patients with anxiety/depression symptoms was 15/41 (36.6%), and patients with facial disorders expressed the highest burden of anxiety/depression symptoms, in 15/35 (42.9%). Factors associated with significantly higher mean body dysmorphic disorder include age<50years (p=0.039), and anxiety/depression (p<0.001), education below high school was associated with higher mean anxiety/depression score (P= 0.031). In a binary logistic regression model, presence of anxiety/depression symptoms was predictive of body dysmorphic disorder (OR=10.0, CI: 4.1-28.2, p<0.001).

Study limitations:

the study is uncontrolled, conducted in a single source of care, thus limiting generalization to nonrelated settings.

Conclusion:

Prevalence of body dysmorphic disorder is high among dermatology patients and most prevalent in facial disorders. Facial diseases are associated with the highest burden of anxiety/depression symptoms. This is a clarion call for dermatologists to routinely assess for body dysmorphic disorder and appropriately refer affected patients to mental health care.

Keywords:
Anxiety; Body dysmorphic disorders; Dermatology

INTRODUCTION

Body dysmorphic disorder (BDD) is a seriously impairing psychiatric condition characterized by excessive preoccupation with a perceived defect in one’s appearance or overemphasis on a slight defect.^1,2 The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classifies body dysmorphic disorder under the obsessive and compulsive spectrum (OCP) disorders, due to its similarity to obsessive-compulsive disorder (OCD).³ Preoccupation per se does not connote the presence of a psychiatric disorder; however, when preoccupation is pathological, an underlying psychiatric condition may be present.⁴ Individuals with BDD are less likely to present to the psychiatrist first, but to dermatologists, plastic surgeons, or dentists, who all have less training to recognize and manage the disorder.⁴

Although individuals with BDD can be preoccupied with the appearance of any part of the body, concern with the skin, hair, and nose is the most common.^5,6 In the skin, the main area of preoccupation is usually the face, despite some reported focus of concern on other areas like the neckline, arms, legs, or back. Common skin conditions that could lead to such preoccupation include acne, skin color, skin marks, wrinkles, or scarring.^5,6 Patients’ concern with hair is mostly about balding or excessive body hair.⁵ Cororve & Gleaves found that women were more likely to be preoccupied with the breasts, hips, legs, and body weight, while men were more concerned about the genitals, excessive body hair, or balding.⁷ A recent study that screened for BDD among patients attending a tertiary institution found that facial flaws were the most common concern, in 62.5% of participants, followed by body asymmetry in 25%.⁸ It is common for individuals with BDD to spend an inordinate amount of time on rituals such as mirror checking or avoiding reflective surfaces, often attempting to hide the perceived deformity with makeup or clothing.^1,9,10 Aside from the distress caused by the imagined body defects, the amount of time spent on rituals to hide them interferes with patients’ ability to function occupationally or socially, and negatively impacts their quality of life.^11,12

Body dysmorphophobia is a common disorder, with a prevalence of 0.7% to 2.4% among community samples.^1,13 Recent studies confirmed a high prevalence of BDD in dermatology and cosmetic surgery settings with a prevalence ranging from 4.52% to 35.16% and female preponderance.^1,2,13,14 BDD has a high rate of psychiatric comorbidity, and extant literature has shown comorbidity with obsessive-compulsive disorder, major depressive disorder, social phobia, anxiety, and suicide.^3,7,10,11 However, because patients’ presentation is usually first to a non-mental health professional, diagnosis may be delayed for several years after onset of the illness.⁴

In Nigeria and Africa as a whole, as elsewhere in world, the published literature on BDD is still scanty, and the disorder has remained underdiagnosed and underreported.¹² Rapid changes in contemporary societies place a higher premium on appearance, and with the recent emergence and availability of ubiquitous social media, studies on feelings towards appearance become a subject of importance. ¹ Therefore, this study is planned to evaluate the prevalence of body dysmorphic disorder and symptoms of anxiety/depression and to determine the sociodemographic and clinical correlates in patients attending the dermatology clinic in a new university teaching hospital in the Southwest of Nigeria.

METHODS

This cross-sectional study was conducted at the Dermatology Unit of the Department of Internal Medicine of the Ladoke Akintola University of Technology (LAUTECH) Teaching Hospital, Ogbomoso, Nigeria. The LAUTECH Teaching Hospital, Ogbomoso, was upgraded from the old General Hospital (a secondary hospital), built in the 1960s. The Teaching Hospital was established to meet the immediate health needs of the people of Oyo North Senatorial district including Ogbomoso land, Oyo, and Oke-Ogun area. The hospital also receives patients from part of Kwara State and the Osun State of Nigeria. The Dermatology Unit and its clinics were established in 2011 and were recently certified for postgraduate training in Dermatology. The Clinic is being run to date by two board-certified dermatologists with more than five years of experience in clinical diagnosis.

A cross-sectional design was made for systematic random sampling of participants. All willing alternate Dermatology Outpatient Clinic patients that met the inclusion criteria and signed the informed consent form were included. We included 114 participants with various skin disorders. Inclusion criteria were: consenting adults with dermatological diseases, age 18 years and above, and absence of preexisting/diagnosed psychiatric disorders or any other chronic or acute debilitating illnesses. The study excluded patients with dermatological disorders below the age of 18 years and those with any preexisting/diagnosed psychiatric disorder or debilitating acute/chronic clinical or surgical illness. Two board-certified dermatologists evaluated and made the diagnosis of skin diseases. Most diagnoses were made clinically, and skin biopsies, scrapings, nail clippings, skin snips, and other tests were ordered to confirm or exclude differential diagnoses in some situations. The study was approved by the Research Ethics Board of the LAUTECH Teaching Hospital, Ogbomoso, with approval number LTH/OGB/EC/14/036.

Clinical assessment: sociodemographic parameters including age, education, marital status, and ethnicity were documented using a semi-structured questionnaire. History was obtained for rash, edema, ulcers, and pruritus, and duration of the symptoms and the diseases was documented in weeks. Participants were examined in daylight for diagnosis of their skin diseases. Anthropometric parameters including weight, height, and waist and hip circumference were documented using standard criteria prescribed by the National Health and Nutrition Examination Survey III. Body mass index (BMI) was calculated using the formula weight/(height²).¹⁵ Clinical diagnosis was noted, and the part of the body most significantly affected by the skin diseases was recorded.

Assessment of symptoms of body dysmorphic disorder.

Participants were evaluated for BDD using the English version of the Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive-Compulsive Scale (BDD-YBOCS).¹⁶ The BDD-YBOCS is a semi-structured, clinician-rated, 12-item instrument designed to assess the severity of BDD symptoms. The first ten items on the instrument assess excessive preoccupation, obsession, and compulsive behaviors related to dissatisfaction with physical appearance, while items 11 and 12 assess insight and avoidance respectively. The 12 items are rated on a 0-4 scale, where 0 indicates no symptoms and 4 indicates extreme BDD symptoms. The total maximum score obtainable is 48 when all the rated items are summed together. BDD was dichotomized as present or absent, defined as present when the BDD total score is >12 and absent when the total score is less than 12. Permission to use the instrument was obtained from the senior author and copyright holder of the original version of the BDD-YBOCS.

Assessment of symptoms of anxiety and depression

Symptoms of coexisting anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS). HADS is a validated and reliable outcome measure developed for detection of the state of anxiety and depression within the medical outpatient setting. It is a 14-item instrument with the first seven questions designed to examine for anxiety and the last 7 for depression. Each of the items is scored 0-3 with 21 as the highest obtainable score and 0 as the lowest.¹⁷ Caseness, a score > 8 for anxiety and depression, was determined based on a large systematic review by Bjelland et al., with sensitivity 0.78 and 0.79 and specificity 0.9 and 0.83 for anxiety and depression, respectively.¹⁸ The questionnaires were briefly pretested in a small population of patients before the commencement of the study.

Statistical analysis

Data were entered and analyzed using the Statistical Package for the Social Sciences (SPSS 18) version 18 (SPSS, Chicago, IL, USA). Frequencies of all the diagnosed skin diseases were estimated. All the categorical variables were analyzed using chi-square statistics, and continuous variables were analyzed using the Student t-test. The continuous skewed data were summarized using Mann-Whitney U statistics. All significant variables in the bivariate analysis were entered into a binary regression model as independent variables, and presence or absence of BDD was set as the dependent variable to determine the predictors of BDD. All the results of interest were represented in tables, and p-values < 0.05 were considered statistically significant.

RESULTS

The recruited participants were predominantly females, 67/114 (58.8%), with a mean age of 37.70±17.47 years. There was no significant difference in the mean age, educational attainment, marital status, ethnicity, or anthropometric parameters of the participants with or without BDD (Table 1).

Table 1
Demographic and clinical characteristics of the study participants

Variables	Total (%)	BDD present	BDD absent	p-value
Mean age ± SD (years)	37.70±17.47	34.61±17.72	39.44±17.21	0.158
Gender
Male	47(41.2)	16 (39.0)	31 (42.5)	0.720
Female	67(58.8)	25 (61.0)	42 (57.5)
Schooling
Less than complete secondary	24 (21.1)	9(22.0)	15(20.5)	0.860
Complete secondary or more	90 (78.9)	32(78.0)	58(79.5)
Marital status
Presently married	57 (50.0)	25(61.0)	32(43.8)	0.102
Single	53 (46.5)	16 (39.0)	37 (50.7)
Divorced	4 (3.5)	0 (0.0)	4 (5.5)
Ethnicity
Yoruba	108 (94.7)	38(92.7)	70(95.9)	0.398
Igbo	1 (0.9)	0(0.0)	1 (1.4)
Hausa	5 (4.4)	3 (7.3)	2 (2.7)
Median duration of symptoms (weeks) [IQR]
Rash (All forms) (weeks)	32.0 [9.5,260]	41.7	41.30	0.935
Pruritus (weeks)	73.0 [21.0,282.0]	21.72	21.37	0.939
Ulcerations (weeks)	2.0 [2.0, 2.0]	19.52	24.20	0.250
Skin edema (weeks)	104 [8.0,520.0]	12.92	10.80	0.472
Mean weight (kilograms)±SD	65.68±15.42	63.19±15.46	67.40±15.31	0.186
Mean height (meters)±SD	1.60±0.21	1.60±0.16	1.61±0.23	0.936
Mean BMI±SD	24.82±4.76	24.18±3.97	25.18±5.16	0.334
Mean waist circumference (centimeters)±SD	81.03±18.01	79.80±8.97	81.81±21.96	0.631
Mean hip circumference (centimeters)±SD	92.66±22.20	91.10±8.11	93.62±27.61	0.622
Mean waist/hip ratio±SD	0.90±0.15	0.88±0.07	0.92±1.88	0.221
Mean BDD Modification of Y-BOC Scales ±SD	9.83±8.47	19.15±6.57	4.60±3.39	<0.001
Mean HADS±SD	7.89±7.01	12.15±8.37	5.51±4.72	<0.001

• BDD-body dysmorphic disorder, Y-BOC - the Yale-Brown Obsessive-Compulsive Scale, SD-standard deviation, %-percentage

Overall median duration of the presenting symptoms for all forms of skin rash was 32.0 weeks (IQR-9.5, 260), pruritus 73.0 weeks (IQR-21.0, 282), skin ulcerations 2.0 weeks (IQR 2, 2), and skin edema 104 weeks (IQR 8.0, 520). There was no significant difference in the mean rank of the duration of symptoms for participants with or without BDD. Participants with BDD had a significantly higher mean HADS score (12.15±8.37 vs. 5.51±4.72, p=0.001) compared to those without it (Table 1).

Table 2 shows the pattern of skin diseases seen in the study subjects. Eczema and related skin diseases 35(30.7%), acne and related conditions 21(18.4%), urticaria 11 (9.64%), fungal infections 10 (8.8%), viral skin infections 8 (7.0%), and rheumatological disorders 7(6.1%) were the six leading skin disorders. Affected sites included trunk 38 (33.3%), face 35 (30.7), limbs 32 (28.1), and generalized disorders 9 (7.9%) (Table 3).

Table 2
Pattern of skin disorders among participants

Skin disorders	Frequency (%)		Skin disorders	Frequency (%)
Eczema and other inflammatory diseases	Total 35 (30.7)		Fungal infections	Total 10 (8.8)
Seborrheic eczema	5(4.38)		Candida intertrigo	1 (0.9)
Atopic eczema	12(10.52)		Pityriasis versicolor	5 (4.38)
Contact dermatitis	3(2.63)		Tinea manuum, unguium	4 (3.50)
Idiopathic hands and feet eczema	5(4.38)		Viral skin diseases	Total 8 (7.0)
Stasis eczema	2(1.75)		Viral warts	5 (4.38)
Drug eruptions	4(3.50)		Genital warts	1 (0.9)
Lichen simplex chronicus and prurigo	3(2.63)		Herpes zoster	2 (1.75)
Exfoliative dermatitis	1(0.9)		Parasitic infestation	Total 4 (3.5)
Acne, sweat glands, and related disorders	Total 21 (18.4)		Lymphatic filariasis	2 (1.75)
Acne vulgaris	16 (14.03)		Onchodermatitis	2 (1.75)
Acne keloidalis nuchae	1(0.9)		Pigmentation disorders	Total 3 (2.6)
Dissecting folliculitis	2(1.75)		Vitiligo	2 (1.75)
Hyperhidrosis	1(0.9)		Exogenous ochronosis	1 (0.9)
Follicular hyperkeratosis	1(0.9)		Urticarias	Total 11 (9.64)
Papulosquamous disorders	Total 6 (5.3)		Rheumatologic disorders	Total 7 (6.1)
Lichen planus	3 (2.63)		Dermatomyositis	1 (0.9)
Lichen nitidus	1 (0.9)		Discoid lupus erythematosus	3 (2.63)
Psoriasis	1 (0.9)		Subacute cutaneous lupus	1 (0.9)
Pityriasis rosea	1 (0.9)		Overlap syndrome	1 (0.9)
Keloid and hypertrophic scars	Total 6 (5.3)		Gout	1 (0.9)
Dermatosis papulosa nigra	1(0.9)		Others	Total 3 (2.6)
Hypertrophic scars	1(0.9)		Ainhum	1 (0.9)
Keloid	4(3.50)		Epidermal naevus	2 (1.75)

Table 3
Prevalence of body dysmorphic disorder and anxiety/depression symptoms among dermatology patients according to affected site

Location of skin diseases	Total		Body dysmorphic disorder				Anxiety and depression
	N (%)		BDD present N (%)	BDD absent N (%)	p-value		HADS present N (%)	HADS absent N (%)	p-value
Face	35 (30.7)		15 (36.6)	20 (27.4)	0.307		15 (42.9)	20 (25.3)	0.061
Trunk	38 (33.3)		14 (34.1)	24 (32.9)	0.890		11(31.4)	27 (34.2)	0.774
Limbs	32 (28.1)		7 (17.1)	25 (34.2)	0.050		7 (20.0)	25 (31.6)	0.202
Generalized	9 (7.9)		5 (12.2)	4 (5.5)	0.279		2 (5.7)	7 (8.9)	0.566
Overall			41 (36.0)				35 (30.7)

• n=number; %-percentage; BDD- body dysmorphic disorder; HADS-Hospital Anxiety and Depression Scale

Overall prevalence of BDD symptoms was 41/114 (36.0%), with the highest prevalence in patients with facial skin disorders (36.6%). Other prevalence rates included conditions on the trunk, 14 (34.1%), and the limbs, 7 (17.1%), and generalized skin diseases, 5 (12.2%). A similar pattern was noted for anxiety/depression: 35 individuals presented symptoms of anxiety and depression, or a prevalence of 30.7%. Prevalence rates for anxiety and depression were highest in patients with facial disorders, 15 (42.9%), followed by the trunk, 11(31.4%), limbs, 7 (20.0%), and generalized skin diseases, 2 (5.7%) (Table 3).

Table 4 shows the sociodemographic and clinical correlates of BDD and anxiety/depression. Participants below the age of 50 years were more likely to have higher mean BDD scores compared to those older than 50 years (10.77±8.91vs 6.96±6.27, p=0.039). Similarly, participants with less than a complete high school education had higher mean HADS scores (10.63±9.21vs7.17±6.17, p=0.031) compared to those with more schooling. The mean BDD score was significantly higher for patients with facial conditions (11.09±9.28, p=0.296) and generalized skin diseases (12.78±10.73, p=0.279), but lower for those with conditions affecting the trunk (9.50±7.50) and limbs (8.03±7.78). Participants with BDD had significantly higher anxiety/depression scores (12.10±8.37 vs. 5.51±4.73, p<0.001). There were no significant differences according to gender, marital status, or disease duration in the mean BDD and HADS scores. Participants with less than complete secondary education scored higher on HADS (p=0.031) compared to those with more schooling (Table 4).

Table 4
Comparison of mean scores on body dysmorphic disorder scale and hospital anxiety and depression scale according to demographic and clinical variables

Variables	Mean BDD ± SD	p-value	Mean HADS ± SD	p-value		Variables	Mean BDD ± SD	p-value	Mean HADS ± SD	p-value
Age		0.039		0.734		Skin ulcerations		0.773		0.867
Under 50 years	10.77±8.91		8.02±8.91			< 2 weeks	10.86±8.39		8.95±7.94
50 years and older	6.96±6.27		7.50±7.69			>2 weeks	12.25±14.97		9.50±15.26
Gender		0.769		0.934		Location of skin diseases
Male	9.55±9.00		7.83±7.68			Scalp and face		0.296		0.218
Female	10.00±8.14		7.94±6.57			Present	11.08±9.33		9.11±7.97
Schooling		0.893		0.031		Absent	9.28±8.06		7.35±6.53
Less than complete secondary	9.63±11.30		10.63±9.21			Trunk		0.768		0.910
Complete secondary or more	9.89±7.62		7.17±6.17			Present	9.50±7.57		8.00±7.24
Marital status		0.160		0.738		Absent	10.00±8.94		7.84±6.95
Married/Widowed	11.14±8.45		8.25±6.57			Limbs		0.157		0.365
Single	8.85±8.52		7.78±7.62			Present	8.03±7.78		6.94±5.28
Ethnicity		0.555		0.087		Absent	10.54±8.67		8.27±7.58
Yoruba	9.72±8.61		7.63±7.00			Generalized skin disease		0.279		0.429
Non-Yoruba	11.83±5.49		12.67±6.12			Present	12.78±10.73		6.11±7.84
Duration of disease		0.458		0.536		Absent	9.58±8.27		8.04±6.96
< 24 weeks	9.93±8.34		9.13±7.52			BDD SCORE				<0.001
> 24 weeks	11.40±9.56		8.10±7.46			>12			12.1±8.37
Duration of symptoms						< 12			5.51±4.73
Pruritus		0.753		0.917
< 52 weeks	9.66±8.57		8.24±8.98
>52 weeks	10.52±8.99		8.00±5.89

• BDD- Body Dysmorphic Disorder;
  HADS-Hospital Anxiety and Depression Scale

In a binary logistic regression model of all significant contributory variables, presence of symptoms of anxiety/depression was predictive of BDD. Participants with symptoms of anxiety and depression were ten times more likely to have BDD compared to those without such symptoms (OR=10.0, CI: 4.1-28.2, p<0.001) (Table 5).

Table 5
Logistic regression of variables associated with body dysmorphic disorder

Variables	B	SE	OR	95% CI		p-value
				Lower limit	Upper limit
Anxiety and depression	2.4	0.5	10.0	4.1	28.2	<0.001
Age	1.0	0.6	2.6	0.9	8.1	0.093
Education	0.1	1.9	1.2	0.3	4.2	0.800

• CI - confidence interval, OR - odds ratio

DISCUSSION

To the best of our knowledge, this was the first study that examined BDD symptoms in dermatology patients in Nigeria. We found a prevalence of 36.0% in a general dermatology clinic in Ogbomoso. This prevalence was similar to but slightly higher than the upper limit of 4.52% to 35.16% documented in dermatology clinic-based studies as found in a recent systematic review.¹⁴ Expectedly, the prevalence in our sample was also higher than 0.7-2.4%, recorded in studies conducted in the general population.^19,20 Previous studies have shown that BDD is more common in patients seeking plastic surgery interventions and those attending dermatology clinics than in the asymptomatic general population.^14,19,20 Cumulative prevalence of BDD in dermatology patients in the present study (36.0%) was close to that reported by Bowe et al. (35.16%) and higher than the 8.81% described by Ozun et al. and 11.94% reported by Phillips et al.^21-23, which included only participants with acne vulgaris. The factors that could affect the prevalence of BDD vary widely according to the assessment methods, study site, societal values, cultural norms, the survey’s setting, and the skin diseases targeted by the study. ^1,23

There were no differences in the current study according to gender, marital status, or body weight between participants with and without BDD, which is consistent with other studies^1,6,24 Patients under 50 years of age had significantly higher mean BDD scores compared to older participants, also corroborating previous studies.^24,25 Corando et al.¹ also found no association between marital status or gender and BDD in their overall analysis, but found that cosmetic patients with BDD were more likely to be single women with low BMI. The higher mean BDD scores among younger individuals might be related to the fact that these people care about their appearance more than older individuals. Contrasting with our findings, Brohede et al. in Sweden also found that BDD patients were more likely to be single, less educated, younger, and unemployed or on sick leave within a small age group.¹¹

In the present study, conditions on the face were associated with the highest prevalence of BDD and anxiety and depression. These findings may be due to the fact that participants with facial conditions do not have their diseases disguised by clothing, with such consequences as social anxiety, shame, social avoidance or isolation, occupational dysfunction, unnecessary cosmetic surgery, and suicide, which are recognized as accompanying BDD.^1,9,11,26 The high prevalence of anxiety and depression in association with facial disorders in this study confirms this assertion. The fact that the location of the conditions was not significantly associated with BDD shows that there are other inherent patient-related traits that determine who develops BDD. The duration of symptoms or diseases also appears to be irrelevant for BDD. Studies have indicated that genetic factors may be essential determinants in the development of BDD.^27,28 Monzani et al. described a genetic overlap between BDD and OCD and found that genetic factors could explain 64% of phenotypic correlation between the two disorders.²⁸ The study also demonstrated a 43% heritability concordance in monozygotic twins.²⁸ An interplay between genetics and the presence of body blemishes in susceptible parts of the body, irrespective of size, severity, and duration of symptoms, might be responsible for the development of BDD. Genetic studies are therefore needed to identify the BDD-related gene among Africans.

Previous studies have shown that BDD patients are highly somatic and distressed by the high level of non-BDD symptoms and poor well-being in domains of depression, anxiety, somatic symptoms, and anger-hostility.^9,11,29 Symptoms of anxiety and depression were highly prevalent (30.7%) in our cohort, and the presence of anxiety and depression predict the existence of BDD in a regression analysis. Similarly, a previous study also corroborated the coexistence of BDD with social phobia and obsessive-compulsive disorder.⁷ Philip et al.²⁹ found depression as the psychiatric disorder most frequently associated with BDD. Perceived ugliness could present with depression and accompany suicidal ideation.³⁰

The study’s limitations include the fact that it was not placebo-controlled and that it was cross-sectional and conducted in a single center, so the results may not be generalizable to unrelated settings. These limitations notwithstanding, the study’s strength lies in its careful selection of participants. It was also the first survey to examine the prevalence of BDD among patients attending a dermatology clinic in Nigeria and it thus produces data in an area yet to be adequately explored in our region. The study employed well-validated, reliable, and tested instruments to generate the data. The study also examined the prevalence of BDD and associations with common comorbidities, which could help provide the basis for collaborative care involving psychiatrists and psychologists.

CONCLUSION

The high prevalence of BDD in this study is a clarion call for dermatologists to reach beyond the clinical treatment of skin conditions and investigate symptoms of BDD by asking patients direct questions on how they feel about their appearance. Timely diagnosis and prompt referral to follow-up by mental health services aim to prevent future adverse consequences.

• *
  Study conducted at the Dermatology Unit, Department of Internal Medicine, Ladoke Akintola University of Technology Teaching Hospital, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria
• Financial support: None.

REFERENCES

• ¹
  Conrado LA, Hounie AG, Diniz JB, Fossaluza V, Torres AR, Miguel EC, et al. Body dysmorphic disorder among dermatologic patients: Prevalence and clinical features. J Am Acad Dermatol. 2010;63:235-43.
• ²
  Dogruk Kacar S, Ozuguz P, Bagcioglu E, Coskun KS, Polat S, Karaca S, et al. Frequency of body dysmorphic disorder among patients with complaints of hair loss. Int J Dermatol. 2016;55:425-9
• ³
  American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th Ed. Washington, D.C: American Psychiatric Association; 2013.
• ⁴
  Munro A, Stewart M. Body dysmorphic disorder and the DSM-IV: the demise of dysmorphophobia. Can J Psychiatry. 1991;36:91-6.
• ⁵
  Kaymak Y, Taner E, Simsek I. Body dysmorphic disorder in university students with skin diseases compared with healthy controls. Acta Derm Venereol. 2009;89:281-4.
• ⁶
  Phillips KA, Diaz SF. Gender differences in body dysmorphic disorder. J Nerv Ment Dis. 1997;185:570-7.
• ⁷
  Cororve MB, Gleaves DH. Body dysmorphic disorder: a review of conceptualizations, assessment, and treatment strategies. Clin Psychol Rev. 2001;21:949-70.
• ⁸
  Thanveer F, Khunger N. Screening for Body Dysmorphic Disorder in a Dermatology Outpatient Setting at a Tertiary Care Centre. J Cutan Aesthet Surg. 2016;9:188-91.
• ⁹
  Brawman-Mintzer O, Lydiard RB, Phillips KA, Morton A, Czepowicz V, Emmanuel N, et al. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995;152:1665-7.
• ¹⁰
  Möllmann A, Dietel FA, Hunger A, Buhlmann U. Prevalence of body dysmorphic disorder and associated features in German adolescents: A self-report survey. Psychiatry Res. 2017;254:263-267.
• ¹¹
  Brohede S, Wyon Y, Wingren G, Wijma B, Wijma K. Body dysmorphic disorder in female Swedish dermatology patients. Int J Dermatol. 2017;56:1387-1394
• ¹²
  Cogwell AR. Body dysmorphic disorder: recognition and treatment. Body dysmorphic disorder: recognition and treatment. Plast Surg Nurs. 2003;23:125-8.
• ¹³
  Mufaddel A, Osman OT, Almugaddam F, Jafferany M. A review of body dysmorphic disorder and its presentation in different clinical settings. Prim Care Companion CNS Disord. 2013;15(4). pii: PCC.12r01464
• ¹⁴
  Ribeiro RVE. Prevalence of Body Dysmorphic Disorder in Plastic Surgery and Dermatology Patients: A Systematic Review with Meta-Analysis. Aesthetic Plast Surg. 2017;41:964-70.
• ¹⁵
  Cdc.gov [Internet]. National Health and Nutrition Examination Survey III. Body Measurements (Anthropometry). [cited 2017 Aug 15]. Available from: https://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/anthro.pdf.
  » https://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/anthro.pdf.
• ¹⁶
  Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997;33:17-22.
• ¹⁷
  Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-70.
• ¹⁸
  Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69-77.
• ¹⁹
  Schieber K, Kollei I, de Zwaan M, Martin A. Classification of body dysmorphic disorder - what is the advantage of the new DSM-5 criteria? J Psychosom Res. 2015;78:223-7.
• ²⁰
  Brohede S, Wingren G, Wijma B, Wijma K. Prevalence of body dysmorphic disorder among Swedish women: a population-based study. Compr Psychiatry. 2015;58:108-15.
• ²¹
  Bowe WP, Leyden JJ, Crerand CE, Sarwer DB, Margolis DJ. Body dysmorphic disorder symptoms among patients with acne vulgaris. J Am Acad Dermatol. 2007;57:222-30.
• ²²
  Uzun O, Basoglu C, Akar A, Cansever A, Ozsahin A, Cetin M, et al. Body dysmorphic disorder in patients with acne. Compr Psychiatry. 2003;44:415-9.
• ²³
  Phillips KA, Dufresne RG Jr, Wilkel CS, Vittorio CC. Rate of body dysmorphic disorder in dermatology patients. J Am Acad Dermatol. 2000;42:436-41.
• ²⁴
  Möllmann A, Dietel FA, Hunger A, Buhlmann U. Prevalence of body dysmorphic disorder and associated features in German adolescents: A self-report survey. Psychiatry Res. 2017;254:263-7.
• ²⁵
  Veale D, Gledhill LJ, Christodoulou P, Hodsoll J. Body dysmorphic disorder in different settings: A systematic review and estimated weighted prevalence. Body Image. 2016 Sep;18:168-86.
• ²⁶
  Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry. 1991;148:1138-49.
• ²⁷
  Monzani B, Rijsdijk F, Harris J, Mataix-Cols D. The structure of genetic and environmental risk factors for dimensional representations of DSM-5obsessive-compulsive spectrum disorders. JAMA Psychiatry. 2014;71:182-9.
• ²⁸
  Monzani B, Rijsdijk F, Iervolino AC, Anson M, Cherkas L, Mataix- Cols D. Evidence for a genetic overlap between body dysmorphic concerns and obsessive-compulsive symptoms in an adult female community twin sample. Am J Med Genet B Neuropsychiatr Genet. 2012;159B:376-82.
• ²⁹
  Phillips KA, Siniscalchi JM, McElroy SL. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Q. 2004;75:309-20.
• ³⁰
  Adebayo KO, Gureje O, Nuhu TF. Body dysmorphic disorder in a Nigerian boy presenting as depression: a case report and literature review. Int J Psychiatry Med. 2012;44:367-72.

Publication Dates

• Publication in this collection
  17 Oct 2019
• Date of issue
  Jul-Aug 2019

History

• Received
  29 Nov 2017
• Accepted
  21 May 2018